JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ZJYL scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 9 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 0% and FCF yield of -1.27%. Investor implication: the business is not currently generating a return on invested capital or positive free cash flow, so there is no cash-yield cushion supporting the current price.
• Whale 13F Flow: 3 / 20. Per the Roarable RQD rating, this pillar measures institutional accumulation and options positioning and scored near the bottom of its range. Investor implication: the rating's flow inputs show little evidence of institutional conviction. No holder data is present in the source data to add detail.
• Insider Conviction: 6 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. Investor implication: insider signal is weak in the rating's inputs.
• Macro Regime Fit: 5 / 20. Per the Roarable RQD rating, beta is 1.0 and sector sensitivity is a factor. Investor implication: the rating does not credit the stock with a favorable macro-regime profile.
• Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 4/9, and Debt/Equity is 0.5. Investor implication: this is the highest-scoring pillar, indicating the balance sheet is the relative strength, though the Piotroski score of 4/9 signals mixed financial-health indicators.

Taken together, the rating frames a stock whose balance sheet is comparatively the least-weak element while its cash generation, institutional flow, and macro fit are all weak. Valuation tradeoffs are visible in the market data: EV/EBITDA is 47.1 per the market data section, which sits alongside an operating margin of 2.9% and a net margin of 5.8%, so the multiple is not supported by strong operating profitability in the reported figures. Upside drivers would need to come from improving cash conversion, which the FCF yield and recent FCF history do not yet show.

Per the profile, ZJYL is a NASDAQ-listed issuer in the Health Care sector, Industrial Specialties industry. Per the recent news wire, the company's products are exported to more than 90 countries and regions, and the company manufactures wheelchairs, with dealers discussing its new models. The source data does not detail the customer base, revenue mix by product, or specific monetization model beyond this.

Per the SEC financials, revenue declined from $23.5M in FY 2024 to $20.7M in FY 2025, and operating income fell from $3.6M to $0.6M over the same period. Net income of $1.2M in FY 2025 exceeded operating income of $0.6M, a gap the source data does not explain. Free cash flow was negative in both FY 2025 ($-3.7M) and FY 2024 ($-1.4M) after $3.1M in FY 2023. Per the market data, gross margin is 29.2%, operating margin 2.9%, and net margin 5.8%, with ROIC at 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9; the Debt/Equity ratio is 0.5, supporting the rating's forensic balance-sheet pillar, though cash and debt balances are not available in source data.

• Kangma equity transfer. Per the recent news wire, the company finalized a Kangma equity transfer and avoids additional share issuance. A separate headline describes an 80% stake transfer that removes the need to issue substitute shares. Both are flagged YELLOW (MARKET WIRE).
• Price action. Per the recent news wire, one report describes the stock ticking up 1.49% to $2.05 while buyers hold a $1.95 floor, while the market data section shows the stock at $1.86, down 2.1%. These figures come from different reports and timestamps.
• Product and export footprint. Per the recent news wire, products are exported to more than 90 countries and regions, and dealers discussed new models.
• Risk watch. One news item (labeled as a TradingView estimates report) carries a summary that is a non-company URL; its content is not usable as a catalyst. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are therefore not available in source data. The main 2nd-order watch item an investor can draw from the provided data is the dependence on the Kangma equity transfer outcome referenced in the news wire, since the company's stated avoidance of substitute share issuance bears on dilution. Investors should also monitor whether declining revenue and operating income continue, given the negative FCF in the two most recent periods.

• What are the cash and debt balances, since both are listed as N/A in the financial history?
• What explains net income of $1.2M exceeding operating income of $0.6M in FY 2025?
• What are the EPS and P/E figures, which are not available in source data?
• What is the terms and timing of the Kangma equity transfer, and what is its effect on share count?
• Which price reference is current, given the news wire reports $2.05 and the market data reports $1.86?